CN114025746B - 抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法 - Google Patents

抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法 Download PDF

Info

Publication number
CN114025746B
CN114025746B CN202080035080.8A CN202080035080A CN114025746B CN 114025746 B CN114025746 B CN 114025746B CN 202080035080 A CN202080035080 A CN 202080035080A CN 114025746 B CN114025746 B CN 114025746B
Authority
CN
China
Prior art keywords
composition
poly
antithrombotic agent
block
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080035080.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114025746A (zh
Inventor
辛启胜
S·乌格
J·贺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudozi Pharmaceutical Co
Original Assignee
Fudozi Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudozi Pharmaceutical Co filed Critical Fudozi Pharmaceutical Co
Publication of CN114025746A publication Critical patent/CN114025746A/zh
Application granted granted Critical
Publication of CN114025746B publication Critical patent/CN114025746B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080035080.8A 2019-05-10 2020-05-08 抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法 Active CN114025746B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962846058P 2019-05-10 2019-05-10
US62/846,058 2019-05-10
PCT/US2020/032049 WO2020231791A1 (fr) 2019-05-10 2020-05-08 Compositions injectables de nanoparticules polymères contenant des agents anti-thrombotiques, procédés et méthodes associés

Publications (2)

Publication Number Publication Date
CN114025746A CN114025746A (zh) 2022-02-08
CN114025746B true CN114025746B (zh) 2023-08-25

Family

ID=73288866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035080.8A Active CN114025746B (zh) 2019-05-10 2020-05-08 抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法

Country Status (3)

Country Link
US (1) US20220218608A1 (fr)
CN (1) CN114025746B (fr)
WO (1) WO2020231791A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133455A2 (fr) * 2008-05-01 2009-11-05 Cadila Healthcare Limited Composition pharmaceutique de clopidogrel
CN102264350A (zh) * 2008-12-26 2011-11-30 株式会社三养社 包含水溶性差的药物的聚合胶束纳米粒子组合物的制备方法
CN102264351A (zh) * 2008-12-26 2011-11-30 株式会社三养社 包含水溶性差的药物的聚合胶束组合物的制备方法
CN105399938A (zh) * 2015-10-16 2016-03-16 姚俊华 一种两亲性嵌段共聚物及其胶束的制备方法和应用
US20170189362A1 (en) * 2014-08-06 2017-07-06 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
CN109010249A (zh) * 2017-06-08 2018-12-18 上海美悦生物科技发展有限公司 注射用达比加群酯药物组合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715566B1 (fr) * 1994-02-03 1996-03-08 Synthelabo Solutions aqueuses concentrées d'argatroban.
EP2480207B1 (fr) * 2009-09-25 2016-11-09 Wisconsin Alumni Research Foundation Encapsulation d'agents thérapeutiques dans des micelles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133455A2 (fr) * 2008-05-01 2009-11-05 Cadila Healthcare Limited Composition pharmaceutique de clopidogrel
CN102264350A (zh) * 2008-12-26 2011-11-30 株式会社三养社 包含水溶性差的药物的聚合胶束纳米粒子组合物的制备方法
CN102264351A (zh) * 2008-12-26 2011-11-30 株式会社三养社 包含水溶性差的药物的聚合胶束组合物的制备方法
US20170189362A1 (en) * 2014-08-06 2017-07-06 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
CN105399938A (zh) * 2015-10-16 2016-03-16 姚俊华 一种两亲性嵌段共聚物及其胶束的制备方法和应用
CN109010249A (zh) * 2017-06-08 2018-12-18 上海美悦生物科技发展有限公司 注射用达比加群酯药物组合物及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
新型口服抗凝剂临床应用的进展;钱方毅;《中国循环杂志》;第27卷(第4期);第246-270页 *

Also Published As

Publication number Publication date
US20220218608A1 (en) 2022-07-14
WO2020231791A1 (fr) 2020-11-19
CN114025746A (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
Kempe et al. In situ forming implants—an attractive formulation principle for parenteral depot formulations
CN100408099C (zh) 含有嵌段共聚物的口服药物组合物
JP2017025071A (ja) 塞栓剤からの薬物送達
JP2009523771A (ja) 凍結乾燥した個体状タキサン類組成物、前記組成物を生成する方法、前記組成物の医薬調剤、前記組成物の調剤用キット。
US11547663B2 (en) Unit aerosol doses for anticoagulation
US20240108603A1 (en) Material and method for treating cancer
CN105663052A (zh) 神经生长因子缓释微球制剂及其制备方法
CN114025746B (zh) 抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法
EP2353588B1 (fr) Préparation à libération prolongée de facteur IX
EP1550444A1 (fr) Systeme de liberation controlee contenant temozolomide
CN1470289A (zh) 一种高分子纳米药物载体和制剂的制备方法
CN113811309B (zh) 用于治疗病毒感染的聚合物制剂及制备方法和用途
CN110101865B (zh) 一种包含有地佐辛药物缓释制剂及其制备方法
CN116829168A (zh) 环孢菌素类似物作为抗血栓形成剂的用途
JP2013525505A (ja) ヘパリンを含む局所用医薬組成物
DE102020124431A1 (de) Extrudierte Depotform mit kontrollierter Wirkstofffreisetzung
KR20120098906A (ko) 서방성 제제
AU2020104375A4 (en) An albendazole nanoliposome freeze-dried powder and its preparation method
CN112451475B (zh) 一种用于治疗空洞型肺结核的长效缓释凝胶
CN111084880B (zh) 一种含有肝素的纳豆激酶组方及其应用
CN101254169A (zh) 含抗结核病药物的缓释剂
CN113694031A (zh) 一种尼莫地平聚合物组合物
WO2021199077A1 (fr) Microsphères de rispéridone, leur procédé de préparation et leurs utilisations
KR20030005997A (ko) 뇌종양 치료용 국소이식형 서방성 항암제제
TW201503900A (zh) 增強治療急性中風之抗血小板藥物之遞送方法及其組合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant